[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628815":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":32,"locations":38,"responsibleParty":62,"collaborators":24,"id":64,"slug":24,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":24,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":24,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":41,"whyStopped":24,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Risankizumab Dose A","EXPERIMENTAL","Participants will receive Dose A of risankizumab via intravenous (IV) infusion.",[13],"Drug: Risankizumab",{"label":15,"type":10,"description":16,"interventionNames":17},"Risankizumab Dose B","Participants will receive Dose B of risankizumab via subcutaneous (SC) injection.",[13],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Risankizumab","Intravenous (IV)",[9],null,{"type":20,"name":21,"description":26,"armGroupLabels":27,"otherNames":24},"Subcutaneous (SC) Injections",[15],[29],{"name":30,"affiliation":5,"role":31},"ABBVIE INC.","STUDY_DIRECTOR",[33],{"name":34,"role":35,"phone":36,"phoneExt":24,"email":37},"ABBVIE CALL CENTER","CONTACT","844-663-3742","abbvieclinicaltrials@abbvie.com",[39,52],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":24},"CenExel ACT- Anaheim Clinical Trials \u002FID# 281821","RECRUITING","Anaheim","California","92801","United States",{"type":47,"coordinates":48},"Point",[49,50],-117.9145,33.83529,{"lat":50,"lon":49},{"facility":53,"status":41,"city":54,"state":55,"zip":56,"country":45,"cosmosGeoPoint":57,"geoPoint":61,"contacts":24},"Cpmi \u002FId# 281783","Miami","Florida","33172",{"type":47,"coordinates":58},[59,60],-80.19366,25.77427,{"lat":60,"lon":59},{"type":63,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100628815",false,"NCT07466550","A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants","A Phase 1 Study in Healthy Subjects to Assess Pharmacokinetics Following Intravenous and Subcutaneous Administration of Risankizumab","Inclusion Criteria:\n\n* Body weight between 40 kg and 100 kg inclusive at screening and upon initial confinement.\n* BMI is ≥ 18.0 to ≤ 32.0 kg\u002Fm2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.\n* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.\n\nExclusion Criteria:\n\n* Exposure to any anti-interleukin-12\u002F23 or anti interleukin-23 treatment for at least one year prior to Screening.\n* Intention to perform strenuous exercise to which the subject is unaccustomed within one week prior to administration of first dose of study treatment or during the study.",true,"ALL","18 Years","65 Years",{"count":75,"type":76},60,"ESTIMATED","INTERVENTIONAL",[79],"PHASE1","The purpose of this study is to compare how the drug moves through the body following risankizumab subcutaneous (SC) and risankizumab intravenous (IV) doses.",[82],"Healthy Volunteer",[82,21],"2026-06-29",{"date":86,"type":87},"2026-07-01","ACTUAL",{"date":89,"type":87},"2026-06-04",{"date":91,"type":76},"2027-01",{"name":5,"class":6},2]